Premium
PRMT5 INHIBITION RESTARTS A PRO‐APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL‐2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA
Author(s) -
Brown F,
Hwang I,
Sloan S,
Hinterschied C,
HelmigMason J,
Long M,
Youssef Y,
Chan W,
Prouty A,
Chung J,
Zhang Y,
ChenKiang S,
DiLiberto M,
Elemento O,
Sehgal L,
Alinari L,
Scherle P,
Vaddi K,
Lapalombella R,
Paik J,
Baiocchi R. A
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.143_2880
Subject(s) - venetoclax , mantle cell lymphoma , cancer research , ibrutinib , protein kinase b , lymphoma , proteasome inhibitor , medicine , biology , apoptosis , chronic lymphocytic leukemia , multiple myeloma , leukemia , genetics